Chemo plus immunotherapy before surgery for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (sintilimab) before surgery helps people with a specific type of lung cancer (EGFR-mutant, non-small cell) that is at a stage where surgery can be considered. The goal is to improve outcomes by shrinking the tumor before the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II to IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) that is not small cell
- Your tumor has an EGFR mutation (either exon 19 deletion or L858R)
- Your PD-L1 level on tumor cells is 1% or higher
- You have not had any prior cancer treatment (chemotherapy, targeted therapy, or immunotherapy)
- Your surgeon believes surgery to remove the tumor is possible and you are healthy enough for it
- You are 18 years or older and have a good performance status (ECOG 0-1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether adding chemotherapy and an immunotherapy drug (sintilimab) to targeted therapy (limertinib) before surgery works better than continuing targeted therapy alone. It is for people with stage II-IIIB EGFR-mutant lung cancer that can be removed with surgery.
This trial tests giving chemotherapy combined with the immunotherapy drug sintilimab before surgery for people with stage IIA to IIIB non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.